| 產(chǎn)品編號 | bs-12008R |
| 英文名稱 | Rabbit Anti-GRIK2 + GRIK3 antibody |
| 中文名稱 | 谷氨酸受體紅藻氨酸離子2/3抗體 |
| 別 名 | GRIK2+GRIK3; G protein coupled receptor family C group 1 member F; GLR 6; GLR6; GLUR 6; GluR-6; GLUR6; Glutamate receptor 6; Glutamate receptor; Glutamate receptor ionotropic kainate 2; Gprc 1f; Gprc1f; GRIK 2; GRIK2; GRIK2 protein; GRIK2_HUMAN; GRM 6; ionotropic kainate 2; EAA5; Excitatory amino acid receptor 5; GLR 7; GLR7; GLU R7; GLUR 7; GluR 7a; GluR-7; GLUR7; GluR7a; Glutamate receptor 7; Glutamate receptor; Glutamate receptor ionotropic kainate 3; GRIK 3; GRIK3; GRIK3_HUMAN; ionotropic kainate 3. |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞膜受體 G蛋白偶聯(lián)受體 G蛋白信號 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human,Mouse,Rat,Rabbit,Pig,Sheep,Cow,Dog,Horse,Monkey) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 99kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human GRIK1 + GRIK2 + GRIK3: 661-760/908 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Glutamate receptors mediate most excitatory neurotransmission in the brain and play an important role in neural plasticity, neural development and neurodegeneration. Ionotropic glutamate receptors are categorized into NMDA receptors and kainate/AMPA receptors, both of which contain glutamate-gated, cation-specific ion channels. Kainate/AMPA receptors are co-localized with NMDA receptors in many synapses and consist of seven structurally related subunits designated GluR-1 to -7. The kainate/AMPA receptors are primarily responsible for the fast excitatory neuro-transmission by glutamate, whereas the NMDA receptors are functionally characterized by a slow kinetic and a high permeability for Ca2+ ions. The NMDA receptors consist of five subunits: epsilion 1, 2, 3, 4 and one zeta subunit. The zeta subunit is expressed throughout the brainstem, whereas the four epsilon subunits display limited distribution. Function: Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA. Subunit: Homotetramer or heterotetramer of pore-forming glutamate receptor subunits. Tetramers may be formed by the dimerization of dimers (Probable). Assembles into a kainate-gated homomeric channel that does not bind AMPA. GRIK2 associated to GRIK5 forms functional channels that can be gated by AMPA (By similarity). Interacts with DLG4. Interacts with NETO2 (By similarity). Interacts (via C-terminus) with KLHL17 (via kelch repeats); the interaction targets GRIK2 for degradation via ubiquitin-proteasome pathway (By similarity). Subcellular Location: Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein. Tissue Specificity: Expression is higher in cerebellum than in cerebral cortex. Post-translational modifications: Sumoylation mediates kainate receptor-mediated endocytosis and regulates synaptic transmission. Sumoylation is enhanced by PIAS3 and desumoylated by SENP1. Ubiquitinated. Ubiquitination regulates the GRIK2 levels at the synapse by leading kainate receptor degradation through proteasome. Phosphorylated by PKC at Ser-868 upon agonist activation, this directly enhance sumoylation. DISEASE: Defects in GRIK2 are the cause of mental retardation autosomal recessive type 6 (MRT6) [MIM:611092]. It is characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. In contrast to syndromic or specific mental retardation which also present with associated physical, neurological and/or psychiatric manifestations, intellectual deficiency is the only primary symptom of non-syndromic mental retardation. MRT6 patients display mild to severe mental retardation and psychomotor development delay in early childhood. Patients do not have neurologic problems, congenital malformations, or facial dysmorphism. Body height, weight, and head circumference are normal. Similarity: Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. GRIK3 subfamily. SWISS: Q13002 Gene ID: 2897 2898 Database links: Entrez Gene: 2898 Human Entrez Gene: 14806 Mouse Omim: 138244 Human SwissProt: Q13002 Human SwissProt: P39087 Mouse Unigene: 98262 Human Unigene: 332838 Mouse Unigene: 87696 Rat |
